

**UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION**

**IN RE: NATIONAL PRESCRIPTION OPIATE
LITIGATION**

MDL No. 2804

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO -101)

On December 5, 2017, the Panel transferred 62 civil action(s) to the United States District Court for the Northern District of Ohio for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* 290 F.Supp.3d 1375 (J.P.M.L. 2017). Since that time, 1,523 additional action(s) have been transferred to the Northern District of Ohio. With the consent of that court, all such actions have been assigned to the Honorable Dan A. Polster.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Northern District of Ohio and assigned to Judge Polster.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Northern District of Ohio for the reasons stated in the order of December 5, 2017, and, with the consent of that court, assigned to the Honorable Dan A. Polster.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Northern District of Ohio. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is
pending at this time, the
stay is lifted.

Jul 09, 2019

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:



John W. Nichols
Clerk of the Panel

I hereby certify that this instrument is a true and correct copy of
the original on file in my office. Attest: Sandy Opacich, Clerk
U.S. District Court, Northern District of Ohio

By: /s/Robert Pitts
Deputy Clerk



**IN RE: NATIONAL PRESCRIPTION OPIATE
LITIGATION**

MDL No. 2804

SCHEDULE CTO-101 – TAG-ALONG ACTIONS

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	<u>CASE CAPTION</u>
GEORGIA MIDDLE			
GAM	1	19-00104	CITY OF DAWSON GEORGIA v. PURDUE PHARMA LP et al
GAM	1	19-00105	CITY OF WARWICK GEORGIA v. PURDUE PHARMA LP et al
GAM	7	19-00089	CITY OF LAKE LAND, GEORGIA v. PURDUE PHARMA LP et al
GAM	7	19-00090	CITY OF NASHVILLE GEORGIA v. PURDUE PHARMA LP et al
LOUISIANA MIDDLE			
LAM	3	19-00388	The University System of Louisiana v. AmerisourceBergen Drug Corporation et al
LAM	3	19-00390	Cameron Parish v. AmerisourceBergen Drug Corporation et al
LOUISIANA WESTERN			
LAW	2	19-00760	Four Winds Tribe Louisiana Cherokee v. Purdue Pharma L P et al
LAW	5	19-00756	C L H G-Acadian L L C et al v. Purdue Pharma L P et al
MICHIGAN EASTERN			
MIE	1	19-11769	County of Cheboygan v. Purdue Pharma L.P. et al
MISSOURI EASTERN			
MOE	4	19-01722	St. Francois County v. Dannie E. Williams, M.D. et al
NEVADA			
NV	2	19-01057	Boulder City v. Purdue Pharma L.P. et al
NV	2	19-01058	City of Mesquite v. Purdue Pharma L.P. et al
NV	2	19-01059	

Opposed 7/8/19

Moapa Band of Paiute Indians v. Purdue Pharma L.P. et al

OKLAHOMA NORTHERN

OKN	4	19-00317	County Commission of Craig County, Oklahoma, The v. Purdue Pharma, L.P. et al
OKN	4	19-00320	County Commission of Payne County, Oklahoma, The v. Purdue Pharma, L.P. et al

TENNESSEE EASTERN

TNE	3	19-00231	Claiborne County, Tennessee v. Amerisourcebergen Drug Corporation et al
-----	---	----------	---

VIRGINIA EASTERN

VAE	3	19-00457	City of Fredericksburg, Virginia v. Purdue Pharma, L.P. et al Opposed 7/8/19
VAE	3	19-00458	Prince George County, Virginia v. Purdue Pharma, L.P. et al Opposed 7/8/19
VAE	3	19-00459	Greensville County, VA v. PURDUE PHARMA, L.P. et al Opposed 7/8/19
VAE	3	19-00463	Mecklenburg County, VA v. Purdue Pharma L.P. et al Opposed 7/8/19

VIRGINIA WESTERN

VAW	3	19-00037	Culpeper County, Virginia v. Purdue Pharma L.P. et al Opposed 7/8/19
VAW	4	19-00029	Charlotte County, Virginia v. Purdue Pharma L.P. et al Opposed 7/8/19